XML 43 R25.htm IDEA: XBRL DOCUMENT
v3.22.1

Note 19 - Related Party Transactions | 12 Months Ended
--- | ---
Dec. 31, 2021
Notes to Financial Statements |
Related Party Transactions Disclosure [Text Block] | NOTE 19. RELATED PARTY TRANSACTIONS Related Party Revenue The following table summarizes information about the Company’s related party revenue and cost of goods sold during the years ended December 31, 2021, 2020 and 2019, respectively (in thousands):
|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
Related party revenue: |  |  |  |  |  |  |  |  |  |  |  |
NeutroPhase |  | $ | 368 |  |  | $ | 524 |  |  | $ | 209 |
Licensing |  |  | — |  |  |  | — |  |  |  | 41 |
Total related party revenue |  | $ | 368 |  |  | $ | 524 |  |  | $ | 250 |
Cost of goods sold |  |  |  |  |  |  |  |  |  |  |  |
NeutroPhase |  | $ | 325 |  |  | $ | 384 |  |  | $ | 176 |
Licensing |  |  | — |  |  |  | — |  |  |  | — |
Total related party expenses |  | $ | 325 |  |  | $ | 384 |  |  | $ | 176 |
Related party accounts receivable was $0.1 million and $0.2 million as of December 31, 2021 and December 31, 2020, respectively. Other Related Party Expenses During the year ended December 31, 2021, the Company purchased KN95 Masks through an affiliate of China Pioneer. As of December 31, 2021, there was no related party account payable as compared to related party accounts payable of $8 thousand as of December 31, 2020. The following table summarizes information about the Company’s other related party expenses excluding stock-based compensation during the years ended December 31, 2021, 2020 and 2019, respectively (in thousands):
|  | Year Ended December 31, |
|  | 2021 |  |  | 2020 |  |  | 2019 |
Commissions to China Kington related to: |  |  |  |  |  |  |  |  |  |  |  |
OP Private Placement |  | $ | — |  |  | $ | — |  |  | $ | — |
June 2019 Private Placement |  |  | — |  |  |  | — |  |  |  | 144 |
August 2019 Private Placement |  |  | — |  |  |  | — |  |  |  | 162 |
Exercise of June 2019 Warrants |  |  | — |  |  |  | 41 |  |  |  | — |
Exercise of 2019 Foreign Warrants |  |  | — |  |  |  | 160 |  |  |  | — |
Promissory Note to Pioneer Pharma (Hong Kong) Company Ltd. |  |  | — |  |  |  | — |  |  |  | 20 |
Total commissions to China Kington |  |  | — |  |  |  | 201 |  |  |  | 326 |
Board Director Bob Wu consulting fee |  |  | — |  |  |  | 50 |  |  |  | 83 |
Total related party expenses |  | $ | — |  |  | $ | 251 |  |  | $ | 409 |
On November 17, 2020, the Company entered into a consulting agreement with Eric Wu. Eric Wu is Partner and Senior Vice President of China Kington and the brother of Bob Wu, who serves on the Company’s Board of Directors. Pursuant to the Agreement, Eric Wu acted as a consultant to the Company in support of product expansion efforts as well as in potential financings and other transaction opportunities. The term of the Agreement was for twelve months. As consideration for his services, the Company granted Eric Wu options exercisable for 300,000 shares of the Company’s common stock under the Company’s 2017 Omnibus Incentive Plan with an exercise price equal to the Company’s closing stock price on the date of the grant and vesting on the one year anniversary of the grant date. Stock-based compensation expense of $152 thousand and $15 thousand was recorded for the year ended December 31, 2021 and 2020, respectively, related to Eric Wu’s options.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -URI http://asc.fasb.org/topic&trid=2122745 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864 + Details
Name: | us-gaap_RelatedPartyTransactionsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration